Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Sequential Immunotherapy Leads to Antigen Loss and Treatment Resistance in Myeloma

September 29th 2023

Whole-genome sequencing of patients with multiple myeloma revealed that sequential immunotherapy was linked with antigen loss associated with treatment resistance and disease relapse.

PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma

September 28th 2023

Treatment with the combination of pomalidomide, bortezomib, and dexamethasone conferred a small, statistically nonsignificant overall survival benefit compared with bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma.

At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma

September 28th 2023

Mezigdomide in combination with either bortezomib and dexamethasone or carfilzomib and dexamethasone showed encouraging responses across multiple dose levels in patients with relapsed/refractory multiple myeloma.

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

September 28th 2023

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma

September 28th 2023

Overall response rates with bispecific antibody monotherapy in patients with extramedullary relapsed/refractory multiple myeloma were lower than ORRs observed across all patients with relapsed/refractory multiple myeloma included in a systematic review evaluating the efficacy of this class of agents in this difficult-to-treat population.

Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma

September 28th 2023

Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.

Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple Myeloma

September 28th 2023

Meral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.

Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma

September 28th 2023

Lisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.

Research Demonstrates the Importance of Effective Frontline Regimens for High-Risk Multiple Myeloma

September 27th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

September 27th 2023

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma

September 25th 2023

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.

Holistic and Multidisciplinary Approaches to Multiple Myeloma Management

September 25th 2023

Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.

Impact of Clinical Trials on the Management of Multiple Myeloma

September 25th 2023

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma

September 22nd 2023

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Dr Chari on the Evolving Role of Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

September 20th 2023

Ajai Chari, MD, discusses the evolving role of bispecific antibodies and CAR T-cell therapies, such as ciltacabtagene autoleucel, in the treatment of patients with multiple myeloma.

Dr Chari on Currently Available Bispecific Antibodies in Multiple Myeloma

September 18th 2023

Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab mafodotin-blmf for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior treatments.

Importance of Clinical Trial Enrollment in Multiple Myeloma

September 18th 2023

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.